We'll know more about the company's medium-term prospects by the end of the year.

The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

The Pairwise Fulcrum® platform includes proprietary gene editing tools, enzymes, and trait libraries that enable precise genetic changes, unlocking plants’ inherent potential and significantly ...

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $56.42, moving +1.58% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 1.05% for the ...

CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...

Scientists have unveiled a CRISPR-based tool, ThermoCas9, capable of pinpointing and removing tumor DNA by detecting cancer-specific chemical markers, potentially sparing healthy cells. In parallel, ...

There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The ...

Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...

Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

CRISPR-Cas12a technology is emerging as a powerful tool for infectious disease diagnostics, combining precision with speed and portability. New one-pot and amplification-free systems are delivering ...